Guardant Health, Inc. (GH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

139.73-8.46 (-5.71%)

At close: 4:00PM EDT

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Commodity Channel Index

View all chart patterns

Performance Outlook

Previous Close	148.19
Open	150.30
Bid	0.00 x 900
Ask	153.37 x 900
Day's Range	139.41 - 150.30
52 Week Range	74.31 - 181.07
Volume	1,014,277
Avg. Volume	938,423

Market Cap	14.129B
Beta (5Y Monthly)	0.49
PE Ratio (TTM)	N/A
EPS (TTM)	-2.60
Earnings Date	May 06, 2021
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	177.80

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

Research Reports

Insider Monkey
Was The Smart Money Right About Piling Into Guardant Health (GH)?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds’ and successful investors’ positions as of the end of the fourth quarter. You can find articles about an individual hedge fund’s trades on numerous financial […]
- Was The Smart Money Right About Philip Morris International Inc. (PM)?
  Insider Monkey
- Was The Smart Money Right About CoStar Group Inc (CSGP)?
  Insider Monkey
Business Wire
Guardant Health Appoints Craig Eagle, MD as Chief Medical Officer
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announces the appointment of Craig Eagle, MD as the company’s new Chief Medical Officer (CMO).
- Cognito Therapeutics Appoints Jonathan Lieber as Chief Financial Officer
  Business Wire
- Drug Farm Appoints Dr. Jeysen Yogaratnam as Chief Medical Officer
  Business Wire
Business Wire
Study Shows Guardant Reveal™ Blood-Only Liquid Biopsy Test Predicts Risk for Colorectal Cancer Recurrence with Industry-Leading Sensitivity
For patients with early-stage colorectal cancer (CRC), the presence of circulating tumor DNA (ctDNA) or minimal residual disease (MRD) after curative intent treatment is becoming an important prognostic biomarker for cancer recurrence, and can also be used to evaluate the potential need for adjuvant treatment in post-surgical patients. Until recently, tests developed to detect MRD required tumor tissue to gain the necessary genomic information needed to accurately identify high-risk patients. A new study led by Massachusetts General Hospital Cancer Center and published in Clinical Cancer Research demonstrates that Guardant Reveal, the first blood-only liquid biopsy to identify MRD, identifies those patients most likely to recur, with industry-leading sensitivity, without the need for tumor tissue.1,2